What are Neurocrine Biosciences's profit margins?

Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.

Where do Neurocrine Biosciences's ratios come from?

Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Neurocrine Biosciences NBIX Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	393.6%+0.2pp	393.4%+1.4pp	392%-2.3pp	394.3%-1.0pp
Operating margin	82.4%-16.4pp	98.8%+56.8pp	42%—	——
Net margin	59.2%-7.1pp	66.4%+27.9pp	38.5%+15.4pp	23.1%-101pp
EBITDA margin	86.9%-16.5pp	103.4%+56.9pp	46.4%—	——
Free cash flow margin	89.7%-7.9pp	97.6%+25.3pp	72.4%+18.1pp	54.2%-51.2pp
Returns
Return on equity	57.2%-7.1pp	64.2%+25.8pp	38.4%+16.3pp	22.1%-104pp
Return on assets	40.7%-5.4pp	46%+19.0pp	27%+12.0pp	15%-61.4pp
Return on invested capital	51.5%-17.8pp	69.3%+38.3pp	31%—	——
Efficiency
Asset turnover	2.7×0.0×	2.8×0.0×	2.8×+0.2×	2.6×+0.1×
Inventory turnover	3.1×-0.5×	3.6×-0.5×	4.2×+1.7×	2.5×+0.5×
Liquidity
Current ratio	13.1×-1.4×	14.5×+3.2×	11.2×-1.5×	12.8×-6.6×
Quick ratio	12.7×-1.4×	14.1×+3.1×	11×-1.4×	12.4×-6.4×
Cash ratio	2.4×+0.2×	2.2×+0.8×	1.4×-1.2×	2.7×-3.8×
Leverage
Debt-to-equity	0.7×+0.1×	0.6×0.0×	0.6×0.0×	0.5×+0.1×
Debt-to-assets	0.5×+0.1×	0.4×0.0×	0.4×0.0×	0.4×+0.1×
Net debt / EBITDA	0.8×+0.2×	0.6×-0.7×	1.2×—	——
Per Share
Book value per share	$112.46+14.5%	$98.22+26.3%	$77.74+25.4%	$62.01+16.6%
Valuation
Market capitalization	$51.78B-2.2%	$52.94B+22.9%	$43.09B+8.0%	$39.89B+11.9%
Enterprise value	$52.17B-2.1%	$53.27B+22.8%	$43.37B+9.1%	$39.75B+14.4%
Price / earnings	134.6×-13.8×	148.3×-168×	316.3×-504×	820.6×+669×
Price / sales	19.8×-4.7×	24.5×-0.3×	24.7×-4.9×	29.6×-3.8×
Price / book	18×-2.8×	20.9×-1.3×	22.2×-4.1×	26.3×-1.2×
EV / EBITDA	91.9×-3.8×	95.7×-123×	218.9×—	——
EV / sales	19.9×-4.7×	24.6×-0.3×	24.9×-4.6×	29.5×-3.1×
Free cash flow yield	18.2%+2.3pp	15.9%+4.2pp	11.7%+4.5pp	7.3%-5.3pp
Earnings yield	12%+1.0pp	10.9%+4.7pp	6.2%+3.1pp	3.1%-11.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Neurocrine Biosciences.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Neurocrine Biosciences's profit margins?: Neurocrine Biosciences (NBIX) runs a 98.2% gross margin and a 25.4% operating margin, with a 21.6% net margin.
Where do Neurocrine Biosciences's ratios come from?: Every ratio is computed from Neurocrine Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.